From Beta Cell Impairment and Destruction to Multiple Organ Lesions in Diabetes: Extent of the Problem

  • Jørn Nerup
  • Torsten Deckert
Part of the Topics in Renal Medicine book series (TIRM, volume 6)

Abstract

The characteristic lesion—insulitis—in the islets of Langerhans at the time of diagnosis of insulin-dependent diabetes mellitus (IDDM) comprises a lymphocytic filtration in the islets occurring together with selective destruction of the beta cells [1]. This finding clearly indicates that immunologic mechanisms may be at work. A wide range of autoimmune phenomena has been described in newly diagnosed IDDM patients [2] and may also be present before IDDM becomes clinically manifest [3]. Human lymphoid cells [4] and antibodies [5] from IDDM patients have been shown to interfere with beta cell function, but evidence that shows a direct cytotoxic effect is lacking. Furthermore, two recent observations make a direct pathogenetic role of islet cell antibodies unlikely: (a) cyclosporine-A-induced remission of endogenous insulin production in newly diagnosed IDDM patients was independent of the presence or absence of islet cell antibodies [6]; and (b) islets in segmental pancreatic grafts exchanged between identical twins discordant for IDDM showed insulitis, but no antibody deposition, in the islets, and occurrence of IDDM in the recipients had no correlation to circulating islet cell antibodies [7]. That beta cells may be destroyed by cytotoxic T-lymphocytes is the other obvious possibility. It has, however, been demonstrated that beta cell destruction is not MHC restricted when grafting MHC-incompatible nonrejectable culture-conditioned islets in animals with diabetes-like syndroms, e.g., in the BB rat and the NOD mouse [8].

Keywords

Beta Cell Diabetic Nephropathy Glomerular Basement Membrane Islet Cell Antibody Persistent Proteinuria 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gepts W, Lecompte PM: The pancreatic islets in diabetes. Am J Med 70: 105–115, 1981.PubMedCrossRefGoogle Scholar
  2. 2.
    Nerup J, Lernmark A, Scott J: In: Gupta S (ed) Immunology of diabetes in experimental animals and man. New York: Plenum, 1984, pp 351–367.CrossRefGoogle Scholar
  3. 3.
    Srikanta S, Ganda OP, Rabizadeh A, Soeldner JS, Eisenbarth GS: First-degree relatives of patients with type 1 diabetes mellitus: islet cell antibodies and abnormal insulin secretion. N Engl J Med 313: 461–464, 1985.PubMedCrossRefGoogle Scholar
  4. 4.
    Boitard C, Chatenoud LM, Debray-Sachs M: In vitro inhibition of pancreatic B cell function by lymphocytes from diabetics with associated autoimmune disease: T cell phenomenon. J Immunol 129: 2529–2531, 1982.PubMedGoogle Scholar
  5. 5.
    Kanatsuna T, Bækkeskov S, Lernmark A, Ludvigsson J: Immunoglobulin from insulin-dependent diabetic children inhibits glucose-induced insulin release. Diabetes 32: 520–524, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Mandrup-Poulsen T, Nerup J, Stiller CR, Marner B, Bille G, Heirnichs D, Martell R, Dupre J, Keown PA, Jenner MR, Rodger NW, Wolfe B, Graffenried BV, Binder C: Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics. Lancet 1: 559–602, 1985.Google Scholar
  7. 7.
    Sibley RK, Sutherland DER, Goetz F, Michael AF: Recurrent diabetes mellitus in the pancreas iso-and allograft: light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 53: 132–144, 1985.PubMedGoogle Scholar
  8. 8.
    Prowse SJ, Bellgrau D, Lafferty KJ: Islet allografts are destroyed by disease occurrence in the spontaneously diabetic BB rat. Diabetes 35: 110–114, 1986.PubMedCrossRefGoogle Scholar
  9. 9.
    Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J: Cytokines cause functional and structural damage to islolated islets of Langerhans. Allergy 40: 424–429, 1985.PubMedCrossRefGoogle Scholar
  10. 10.
    Mandrup-Poulsen T, Bendixen G, Nerup J, Egeberg J, Nielsen JH: Mechanisms of pancreatic islet cell destruction: dose-dependent cytotoxic effect of soluble blood mononuclear cell mediators on isolated islets of Langerhans. Allergy 41: 250–259, 1986.PubMedCrossRefGoogle Scholar
  11. 11.
    Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH: Affinity-purified human interleukin 1 is cytotoxic to isolated islets of Langerhans. Diabetologia 29: 63–67, 1986.PubMedCrossRefGoogle Scholar
  12. 12.
    Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M: Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232: 1545–1547, 1986.PubMedCrossRefGoogle Scholar
  13. 13.
    Mandrup-Poulsen T, Egeberg J, Nerup J, Bendtzen K, Nielsen JH, Dinarello CA: Ultra-structural studies of time-course and cellular specificity of interleukin-1 mediated islet cytotoxicity. Acta Pathol Microbiol Immunol Scand (in press), 1987.Google Scholar
  14. 14.
    Klempner MS, Dinarello CA, Henderson WR, Gallin JI: Stimulation of neutrophil oxygen-dependent metabolism by human leukocytic pyrogen. J Clin Invest 64: 996–1002, 1979.PubMedCrossRefGoogle Scholar
  15. 15.
    Malaisse WJ: Alloxan toxicity to the pancratic B-cell: a new hypothesis. Biochem Pharmacol 31: 3527–3534, 1982.PubMedCrossRefGoogle Scholar
  16. 16.
    Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T: Diabetic nephropathy in type 1 (insulin-dependent) diabetes mellitus: an epidemiological study. Diabetologia 25: 496–501, 1983.PubMedCrossRefGoogle Scholar
  17. 17.
    Borch-Johnsen K, Andersen PK, Deckert T: The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28: 590–596, 1985.PubMedCrossRefGoogle Scholar
  18. 18.
    Parving HH, Andersen AR, Smidt UM, Christiansen JS, Oxenboll B, Svendsen PAa: Diabetic nephropathy and arterial hypertension: the effect of antihypertensive treatment. Diabetes [Suppl 2] 32: 83–87, 1983.Google Scholar
  19. 19.
    Borch-Johnsen B, Kreiner S: Proteinuria: a preidictor of cardiovascular mortality in insulin-dependent diabetes mellitus. Brit Med J 294: 1651–1654, 1987.CrossRefGoogle Scholar
  20. 20.
    Jensen J, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T: Coronary heart disease in young type l (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 30: 144–148, 1987.PubMedCrossRefGoogle Scholar
  21. 21.
    Kofoed-Enevoldsen A, Jensen T, Borch-Johnsen K, Deckert T: Incidence of retinopathy in type 1 (insulin-dependent) diabetes association with clinical nephropathy. Diabetic Complications (in press), 1987.Google Scholar
  22. 22.
    Borch-Johnsen K, Nissen H, Henriksen E, Kreiner S, Sailing N, Deckert T, Nerup J: The natural history of insulin-dependent diabetes mellitus in Denmark: long-term survival with and without late diabetic complications. Diabetic Med 4: 207–210, 1987.Google Scholar
  23. 23.
    Feldt-Rasmussen B: Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 29: 282–286, 1986.PubMedCrossRefGoogle Scholar
  24. 24.
    Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Kverneland A, Bent-Hansen L, Jensen T, Kofoed-Enevoldsen A: Glycaemic control and microvascular complications in type 1 diabetic patients. Lecture given at the International Workship on Diabetic Angiopathy in Children, Berlin, September 1986. Pediatr Adolescent Endocrinol (in press), 1986.Google Scholar
  25. 25.
    Rohrbach R: Reduced content and abnormal distribution of anionic sites (acid proteoglycans) in the diabetic glomerular basement membrane. Virchows Arch [Cell Pathol] 51: 127–135, 1986.CrossRefGoogle Scholar
  26. 26.
    Myers BD, Winetz JA, Chui F, Michaels AS: Mechnisms of proteinuria in diabetic nephropathy: a study of glomerular barrier function. Kidney Int 21: 633–641, 1982.PubMedCrossRefGoogle Scholar
  27. 27.
    Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M: Glomerular size and charge selectivity in insulin-dependent diabetes melliuts. Kidney Int (in press), 1987.Google Scholar
  28. 28.
    Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Kverneland A, Frekjær Thomsen O: Clinical assessment and prognosis of complications of diabetes. Transplant Proc 18: 1636–1638, 1986.Google Scholar
  29. 29.
    Feldt-Rasmussen B, Baker L, Deckert T: Exercise as a provocative test in early renal disease in type 1 (insulin-dependent) diabetes: albuminurie, systemic and renal haemodynamic responses. Diabetologia 28: 389–396, 1985.PubMedCrossRefGoogle Scholar
  30. 30.
    Deckert T, Parving HH, Frekjær Thomsen O, Jorgensen HE, Brun C, Thomsen AC: Renal structure and function in type 1 (insulin-dependent) diabetic paients: a study of 44 kidney biopsies. Diabetic Nephropathy 4: 163–168, 1985.Google Scholar
  31. 31.
    Lovett DH, Szamel M, Ryan JL, Sterzel RB, Gemsa D, Resch K: Interleukin 1 and the glomerular mesangium. I. Purification and characterization of a mesangial cell-derived auto-growth factor. J Immunol 136: 3700–3705, 1986.PubMedGoogle Scholar
  32. 32.
    Tyler JA: Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. Biochem J 227: 869–878, 1985.PubMedGoogle Scholar
  33. 33.
    Frekjær Thomsen O, Andersen AR, Christiansen JS, Deckert T: Renal changes in long-term type 1 (insulin-dependent) diabetic patients with and without clinical nephropathy: a light microscopic, morphometric study of autopsy material. Diabetologia 26: 361–365, 1984.Google Scholar
  34. 34.
    Mathiesen ER, Oxenboll B, Johansen K, Svendsen PAa, Deckert T: Incipent nephropathy in type i (insulin-dependent) diabetes. Diabetologia 26: 406–410, 1984.PubMedCrossRefGoogle Scholar
  35. 35.
    Feldt-Rasmussen B, Mathiesen ER, Deckert T: Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 2: 1300–1304, 1986.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1988

Authors and Affiliations

  • Jørn Nerup
  • Torsten Deckert

There are no affiliations available

Personalised recommendations